Académique Documents
Professionnel Documents
Culture Documents
ISSN- 0975-1491
ResearchArticle
ANTIBIOTICTHERAPYINPNEUMONIA:ACOMPARATIVESTUDYOFORALANTIBIOTICSINA
RURALHEALTHCARECENTRE
ADITYAUDUPA1,*PANKAJGUPTA2
DepartmentofPharmacology,B.J.MedicalCollegeandSassoonGeneralHospital,Pune,India400607,DepartmentofPreventiveand
SocialMedicine,SethG.S.MedicalCollegeandKEMHospital,Mumbai,Email:draaditya.udupa@gmail.com,
pankajgupta85@rediffmail.com
Received:29Feb2011,RevisedandAccepted:30March2011
ABSTRACT
Pneumoniaisaninfectionofthepulmonaryparenchyma.Thecurrentrecommendationsfortreatingpneumoniaonanoutpatientbasisaretousea
respiratoryfluoroquinoloneoramacrolideoralactam.ThestudywasconductedintheRuralHealthTrainingCentreinThaneDistricttoassess
theefficacyoftherecommendeddrugsforpneumoniaincomparisontoeachother.Allpatientswithapresumptivediagnosisofpneumoniawere
askedtoundergoachestXray,sputummicroscopyandleukocytecount,tomakeadefinitivediagnosisofpneumonia.Thepatientswhofitintothe
inclusioncriteriawererandomizedandeithergivenamacrolide[clarithromycin(500mgPObid)orazithromycin(500mgPOonce,then250mg
od)]ORarespiratoryfluoroquinolone[levofloxacin(750mgPOod)]ORalactam[highdoseamoxicillin(1gtid)].Atotalof31patientswere
studied. No significant difference was detected regarding clinical success or mortality, regardless of atypical coverage or between antibacterial
classes with similar atypical coverage. It was not possible to demonstrate any advantage of specific antibacterial for mild communityacquired
pneumonia in relatively healthy outpatients. In mildtomoderate cases of outpatienttreated communityacquired pneumonia, it might be most
appropriatetoselectantibacterialaccordingtosideeffects,patientpreferences,availabilityandcost.
Keywords:Pneumonia,Antibacterial,Treatment,Outpatients.
INTRODUCTION
The patients who fit into the inclusion criteria were randomized
and were given, either a macrolide [Clarithromycin (500 mg PO
BD) or Azithromycin (500 mg PO once, then 250 mg OD)] or a
respiratoryfluoroquinolone[levofloxacin(750mgPOOD)]ora
lactam[highdoseamoxicillin(1gTID)].Thepatientswereasked
totakethefirstdoseintheOPDitselfandwereaskedtoreporton
thethirdandthefifthday.Aclinicalcheckupwasdoneduringthe
subsequentvisits.
MATERIALSANDMETHODS
DuringthecourseofthreemonthsfromJune09toSep09atotalof
180patientscamewithcomplaintsoffeverwithcough.Onfurther
checkup43werediagnosedashavingclinicalsignsofpneumonia.
Outofthese2wereimmediatelyreferredtothetertiarycentrefor
further treatment. Out of the remaining 41, six patients did not
show either consolidation or organisms on sputum smear hence
were not included in the study. Thirty five patients received
antibiotictherapyfortheirconditionandoutofthese35patients,
one patient was referred to the tertiary care centre due to
increasingbreathlessnesstheverysamedayofstartingantibiotic
therapy. Two patients did not come for the second visit and one
more did not come for the final visit at day 5.The final data was
analysedforthirtyonepatients.
RESULTS
Guptaetal.
IntJPharmPharmSci,Vol3,Suppl3,2011,156158
Table1:Characteristicsoftheenrolledpatients
Parameter
Totalpatients
Male
Female
Age
1821
2131
3141
4155
PreviousDiabetes
Previoushypertension
WithpatchonchestXray
Withsputumshowingorganismongramstain
Grampositiveorganism
Gramnegativeorganism
Noofpatients(percentvalue)
31
21(67.74)
10(32.26)
6(19.35)
7(22.58)
11(35.48)
7(22.58)
2(6.45)
3(9.67)
22
20
14
6
Table2:Characteristicsofpatientsallottedtodifferenttreatmentgroups
Antibiotic
Noof
patients
Averageage
AverageWBC
count
Noorganismongram
stain
Grampositive
organism
Clarithromycin
Azithromycin
Levofloxacin
Highdoseamoxicillin
8
7
7
9
32.20
29.42
33.67
38.87
11000
10800
10120
11980
3
2
2
4
3
4
2
5
Gram
Negative
organism
2
1
3
0
Table3:Monitoringresponseofdifferenttreatmentsonthefirst(day3)andsecond(day5)visit
Antibiotic
Clarithromycin
Azithromycin
Levofloxacin
Highdoseamoxicillin
Day0
11000
10800
10120
11980
WBCcount
Day3
7000
4300
4230
6500
Day5
5500
4000
3850
4950
Day0
101.4
101.3
99.8
101.1
Temperature
Day3
98.7
98.8
99.2
99.9
Day5
97.8
97.5
98.4
98.6
Table4:Monitoringresponseofdifferenttreatmentsonthefirst(day3)andsecond(day5)visit
Antibiotic
Clarithromycin
Azithromycin
Levofloxacin
Highdoseamoxicillin
Cough(Noofpatients)
Day0
Day3
8
6
7
4
7
5
9
7
Day5
2
2
4
3
Respiratoryrate(Average)
Day0
Day3
Day5
21
17
15
23
18
14
21
18
16
24
19
17
Bronchialbreathing(Noofpatients)
Day0
Day3
Day5
8
4
1
7
4
2
7
4
2
9
6
3
Table5:Adverseeventsnoted
Drug
Clarithromycin
Azithromycin
Levofloxacin
Highdoseamoxicillin
Diarrhoea/Abdominalpain
2
3
2
6
Adverseevents
Rash/Skineruptions
0
1
0
1
Headache
2
1
3
0
CVS
0
0
0
0
DISCUSSION
PneumoniaisafrequentclinicalprobleminIndiawithanincidence
of16% 3.Thestandardtherapyofpneumoniaisempiricaltreatment
ofthepatientsinceadefinitivediagnosismaynotbepossibleinall
casesandisalsotimeconsumingwheneveravailable1,2.
Insummarynosignificantdifferencewasdetectedregardingclinical
success or mortality, regardless of atypical coverage or between
antibacterial classes with similar atypical coverage. It was not
possible to demonstrate any advantage of specific antibacterial for
mild communityacquired pneumonia in relatively healthy
outpatients. The need for coverage of atypical pathogens in this
setting was not apparent. In mildtomoderate cases of outpatient
treated communityacquired pneumonia, it might be most
157
Guptaetal.
IntJPharmPharmSci,Vol3,Suppl3,2011,156158
2.
REFERENCES
3.
1.
158